Startups
Predicting Phase III clinical trials immediately post-discovery with 99.94% proven accuracy, using virtual cells, organs, and patients. Our proprietary Phase Advance Predictive Technology Platform™ powers complex mathematical models of disease progression in silico to accurately predict day-to-day responses at individual patient levels in future phase III trials. These in silico clinical trials predict precise endpoints […]
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 22, 2026 | Leaf4Life Engages Phase Advance To Predict Clinical Outcomes for 16 Phase 3 Trials | Phase Advance layers non-LLM AI modules over cradle-to-grave nonlinear mathematical models of human lifespans to predict how newly discovered drugs will perform in Phase 3 clinical trials. Leaf4Life is a biopharmaceutical company dedicated ... |
| Jan 13, 2026 | Ainnocence and Phase Advance Enter Industry-First AI Collab to Reduce Drug Development Timeline and Clinical Trial Risk | Phase Advance Logo Ainnocence Logo Dr. Tawanda Gumbo, Phase Advance CEO And Dr. Lurong Pan, Ainnocence CEO The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for i... |
Reviews 0
FAQ about Phase Advance AI
What has the press written about Phase Advance AI?
Parsers VC has collected 3 articles mentioning Phase Advance AI, among them “Leaf4Life Engages Phase Advance To Predict Clinical Outcomes for 16 Phase 3 Trials” (Jun 22, 2026) and “Ainnocence and Phase Advance Enter Industry-First AI Collab to Reduce Drug Development Timeline and Clinical Trial Risk” (Jan 13, 2026).
Is Phase Advance AI still active?
Yes, Phase Advance AI is active; its latest activity on Parsers VC dates from Oct 20, 2026.